HoldsUp

Dr. Tyna Moore · 2026-03-05 · Tyna Moore (host), Natalie Jill

Stop Dieting Like It’s 1995: Midlife Fat Loss Looks Different Now | Natalie Jill

19 research-tied claims examined: 5 contradicted 6 context 7 supported 1 unverified

5

Contradicted by research

0:19:24Tyna Moore (host)contradictedmoderate

Ozempic face is caused by GLP-1 receptor agonists directly inducing sarcopenia in facial muscles.

"now that we've added GLP-1s on board, GLP-1s are inducing sarcopenia. So that Ozempic face, it's not just from extreme fat loss or fast fat loss and losing all your fat pads, which you never get back by the way, it is from inducing sarcopenia in the muscles of your face." (said at 0:19:24)

The claim that 'Ozempic face' is driven by GLP-1 receptor agonists inducing sarcopenia in facial muscles is contradicted by anatomical and aesthetic literature. Clinical and anatomical reviews establish that facial aesthetic changes following GLP-1 receptor agonist use are primarily caused by rapid, substantial loss of subcutaneous and deep facial fat pads (adipose deflation) along with skin laxity resulting from rapid overall weight loss, rather than direct drug-induced sarcopenia of the facial musculature. Furthermore, systematic reviews on body composition during incretin therapy show that while total lean mass decreases alongside significant fat loss (as expected with any major caloric deficit and weight reduction), GLP-1 therapies do not disproportionately degrade muscle relative to other weight-loss methods and do not selectively atrophy facial muscles.

0:21:36Tyna Moore (host)contradictedmoderate

GLP-1 receptor agonists deplete sex hormones including estrogen, testosterone, and progesterone when taken by individuals who are not obese or severely metabolically compromised.

"when you go into a GLP-1 journey at a regular dose and you are obese and you're severely metabolically compromised, it will improve your hormonal profile. If you go into it not in that shape, it depletes your hormones." (said at 0:21:36)

While GLP-1 receptor agonists (and dual GIP/GLP-1 agonists) can improve sex hormone profiles and testosterone levels in men with obesity and metabolic hypogonadism, there is no evidence that GLP-1 receptor agonists deplete sex hormones (testosterone, estrogen, progesterone) in individuals who are not obese. In a randomized, double-blind, placebo-controlled crossover trial of healthy normal-weight men receiving the GLP-1 receptor agonist dulaglutide for 4 weeks (PMID: 39232425), hypothalamic-pituitary-gonadal axis hormones (total testosterone, LH, FSH) remained fully within the normal range with no significant difference compared to placebo.

0:22:17Tyna Moore (host)contradictedvery low

In underfed mice, GLP-1 administration decreases kisspeptin, causing sex hormones to drop.

"there is a mechanism that we have seen specifically in the data where it decreases kisspeptin and that's a sort of a signaling molecule for your body to make hormones. So, anyway, and that's in a that's in an underfed body. So, the study took mice and they gave them GLP-1s and then they were well-fed or they were underfed. And in the underfed mice, their hormones dumped out cuz their kisspeptin dumped out." (said at 0:22:17)

The speaker mischaracterizes the relationship between GLP-1 receptor signaling, fasting, and kisspeptin. In rodent studies, GLP-1 receptor agonists (such as liraglutide) directly activate and stimulate hypothalamic arcuate nucleus kisspeptin (Kiss1) neurons and increase Kiss1 expression, rather than decreasing them. Hypothalamic kisspeptin expression and downstream sex hormones (such as luteinizing hormone) are suppressed by fasting and negative energy balance itself; when researchers administered a GLP-1 receptor agonist to fasted mice, it simply failed to rescue or reverse the fasting-induced suppression of luteinizing hormone.

0:30:33Tyna Moore (host)contradictedmoderate

Studies demonstrate that nearly 50% of patients receiving standard doses of GLP-1 receptor agonists develop small intestinal bacterial overgrowth (SIBO) if they did not have it prior to treatment.

"If you have SIBO, small intestinal bacterial overgrowth, we we have seen in the studies that people in standard doses of GLP-1s, almost 50% of them end up with SIBO if they didn't start with it." (said at 0:30:33)

The claim that nearly 50% of patients on GLP-1 receptor agonists develop small intestinal bacterial overgrowth (SIBO) is contradicted by published epidemiological data. While GLP-1 receptor agonists are associated with a statistically significant relative increase in SIBO risk compared to other second-line diabetes treatments due to delayed gastrointestinal motility, the absolute incidence is very rare. In a large propensity-score matched cohort study of 216,173 patients per group (PMID 40941750), the incidence of diagnostically confirmed SIBO in patients initiating GLP-1 or dual GLP-1/GIP receptor agonists was 0.177 per 1,000 patient-years (less than 0.02% per year), far below the claimed 50%.

0:31:31Tyna Moore (host)contradictedmoderate

Small intestinal bacterial overgrowth (SIBO) directly induces type 2 diabetes and metabolic dysfunction.

"SIBO induces type 2 diabetes and metabolic dysfunction." (said at 0:31:31)

There is no evidence that small intestinal bacterial overgrowth (SIBO) directly induces type 2 diabetes. Rather, the established clinical and epidemiological relationship is inverted: diabetes mellitus—through autonomic neuropathy, altered gastrointestinal motility, and chronic hyperglycemia—is a recognized predisposing risk factor for the development of SIBO. While gut dysbiosis and SIBO have cross-sectional associations with impaired beta-cell function and insulin resistance, causal induction of type 2 diabetes by SIBO has not been demonstrated.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.